Holen Sie sich die Stockscreener-App
18.76
2.04%
-0.39
Schlusskurs vom Vortag:
$19.15
Offen:
$19
24-Stunden-Volumen:
307.02K
Relative Volume:
0.97
Marktkapitalisierung:
$603.32M
Einnahmen:
$4.12M
Nettoeinkommen (Verlust:
$-56.68M
KGV:
-3.3845
EPS:
-5.5429
Netto-Cashflow:
$-51.44M
1W Leistung:
-8.89%
1M Leistung:
+2.79%
6M Leistung:
-18.61%
1J Leistung:
-29.84%
1-Tages-Spanne:
$18.12
$20.57
1-Wochen-Bereich:
$18.12
$22.14
52-Wochen-Spanne:
$13.37
$32.27
Dianthus Therapeutics Inc Stock (DNTH) Company Profile
Firmenname
Dianthus Therapeutics Inc
Sektor
Branche
Telefon
929-999-4055
Adresse
7 TIMES SQUARE, NEW YORK
Vergleichen Sie DNTH mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DNTH
Dianthus Therapeutics Inc
|
18.76 | 655.74M | 4.12M | -56.68M | -51.44M | -5.5429 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Dianthus Therapeutics Inc Stock (DNTH) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-02 | Eingeleitet | William Blair | Outperform |
| 2024-12-20 | Eingeleitet | TD Cowen | Buy |
| 2024-10-03 | Eingeleitet | Oppenheimer | Outperform |
| 2024-07-26 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-06-27 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-05-16 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-02-15 | Eingeleitet | Stifel | Buy |
| 2023-12-26 | Eingeleitet | Jefferies | Buy |
| 2023-11-22 | Eingeleitet | Wedbush | Outperform |
| 2023-10-30 | Eingeleitet | Guggenheim | Buy |
| 2023-09-28 | Eingeleitet | Raymond James | Outperform |
| 2022-08-25 | Herabstufung | Goldman | Buy → Neutral |
| 2022-01-06 | Hochstufung | Goldman | Neutral → Buy |
| 2021-08-20 | Fortgesetzt | Goldman | Neutral |
| 2021-08-03 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-07-22 | Bestätigt | B. Riley Securities | Buy |
| 2021-06-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-06-15 | Eingeleitet | BTIG Research | Buy |
| 2021-05-18 | Eingeleitet | B. Riley Securities | Buy |
| 2021-01-07 | Eingeleitet | Mizuho | Buy |
| 2020-06-08 | Hochstufung | Goldman | Neutral → Buy |
| 2019-03-25 | Herabstufung | Goldman | Buy → Neutral |
| 2019-03-15 | Eingeleitet | Raymond James | Outperform |
Alle ansehen
Dianthus Therapeutics Inc Aktie (DNTH) Neueste Nachrichten
Can trapped investors hope for a rebound in Dianthus Therapeutics Inc.Swing Trade Timing with Daily Forecast - Newser
Can you recover from losses in Dianthus Therapeutics Inc.Daily Entry Opportunity Forecasting Tool - Newser
How institutional ownership impacts Dianthus Therapeutics Inc. stockDaily Profit Watch With Forecast Confidence - Newser
Will earnings trigger a reversal in Dianthus Therapeutics Inc.Predictable Income Summary for Long-Term Trades - Newser
Dianthus Therapeutics (DNTH) to Release Earnings on Thursday - MarketBeat
Relative strength of Dianthus Therapeutics Inc. in sector analysisHigh Yield Signals with Entry Timing - Newser
Custom watchlist performance reports with Dianthus Therapeutics Inc.High Return Idea With Technical Filter - Newser
Real time breakdown of Dianthus Therapeutics Inc. stock performanceQuarterly Investment Outlook and Key Summary - Newser
Brokerages Set Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Target Price at $53.00 - MarketBeat
Why Dianthus Therapeutics Inc. stock attracts strong analyst attentionFree Accurate Buy Point for Momentum Stocks - Newser
What earnings revisions data tells us about Dianthus Therapeutics Inc.Buy Strategy with Smart Exit Timing - Newser
What makes Dianthus Therapeutics Inc. stock price move sharplyCapital Secure Pattern Signal Analysis Sheet - Newser
Has Dianthus Therapeutics Inc. formed a bullish divergenceFree Expert Verified Stock Trade Ideas - Newser
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
Dianthus Therapeutics Inc. stock trend forecastFree Sector Rotation Based Trading Opportunities - Newser
Is Dianthus Therapeutics Inc. still worth holding after the dipFree Reliable Investment Entry Point Signals - Newser
Dianthus Therapeutics Reports Q2 2025 Financial Results - TipRanks
Dianthus Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Promising Outlook for Dianthus Therapeutics: Buy Rating on Claseprubart’s Potential in gMG - TipRanks
Dianthus Therapeutics: Promising Prospects with DNTH103 and Strong Financial Position Support Buy Rating - TipRanks
Dianthus Therapeutics, Inc. (DNTH) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 Financial Results - The Manila Times
Dianthus Therapeutics Nears Critical Phase 2 Trial Results: $309M Cash Runway Powers Multiple Clinical Programs - Stock Titan
Earnings Preview: Dianthus Therapeutics, Inc. (DNTH) Q2 Earnings Expected to Decline - Yahoo Finance
Dianthus Therapeutics (DNTH) Expected to Announce Earnings on Thursday - Defense World
Is Dianthus Therapeutics Inc. stock poised for growthFree Chart Alert System With Entry Targets - Newser
Dianthus Therapeutics Inc. stock trendline breakdownFree Triple Digit Return Stock Predictions - Newser
How moving averages guide Dianthus Therapeutics Inc. tradingDeep Learning Stock Forecast for Investors - Newser
Should I hold or sell Dianthus Therapeutics Inc. stock in 2025Discover stocks with strong growth potential - Jammu Links News
What drives Dianthus Therapeutics Inc. stock priceRapid-fire capital growth - Jammu Links News
How institutional ownership impacts Sionna Therapeutics Inc. stockFree Short Term Trading Opportunity Watch - Newser
What are the technical indicators suggesting about Dianthus Therapeutics Inc.Remarkable growth - Jammu Links News
Finanzdaten der Dianthus Therapeutics Inc-Aktie (DNTH)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.24%
3.39%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):